{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:18:34Z","timestamp":1795112314070,"version":"4.10.3"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Dapagliflozin (a sodium-glucose cotransporter-2 [SGLT2] inhibitor) represents the most recently approved class of oral medications for the treatment of type 2 diabetes. Dapagliflozin lowers plasma glucose concentration by inhibiting the renal reuptake of glucose in the proximal renal tubules. In 2015, the US Food and Drug Administration released a warning concerning a potential increased risk of ketoacidosis in patients taking this medication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We present the case of a 23-year-old woman with type 2 diabetes treated with dapagliflozin (10\u200amg, once a day) for 2 years who presented to the emergency department with abdominal pain.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>We diagnosed her with severe ketoacidosis with a normal glucose level (177\u200amg\/dL) due to dapagliflozin, accompanying acute pancreatitis due to hypertriglyceridemia. We concluded that the precipitating factor for euglycemic ketoacidosis was pseudomembranous colitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>She was treated with intravenous infusions of insulin, isotonic saline, and sodium bicarbonate as diabetic ketoacidosis treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>She was in shock with severe metabolic acidosis. After continuous renal replacement therapy, the uncontrolled metabolic ketoacidosis was treated, and she is currently under follow-up while receiving metformin (500\u200amg, once a day) and short- and long-acting insulins (8 units 3 times and 20 units once a day).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We report an unusual case of SGLT2 inhibitor-induced euglycemic ketoacidosis recovered by continuous renal replacement therapy in a patient with type 2 diabetes and recurrent acute pancreatitis due to hypertriglyceridemia. We diagnosed a rare complication of the SGLT2 inhibitor in a patient with type 2 diabetes in whom uncontrolled metabolic ketoacidosis could be effectively managed via continuous renal replacement therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014150","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T03:06:45Z","timestamp":1547694405000},"page":"e14150","source":"Crossref","is-referenced-by-count":11,"title":["Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin"],"prefix":"10.1097","volume":"98","author":[{"given":"Sang Mok","family":"Yeo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Keimyung University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayeon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keimyung University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hyuk","family":"Paek","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keimyung University School of Medicine"},{"name":"Keimyung University Kidney Institute, Daegu, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Yeong","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keimyung University School of Medicine"},{"name":"Keimyung University Kidney Institute, Daegu, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungyeup","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keimyung University School of Medicine"},{"name":"Keimyung University Kidney Institute, Daegu, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Bae","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keimyung University School of Medicine"},{"name":"Keimyung University Kidney Institute, Daegu, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyubok","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Keimyung University School of Medicine"},{"name":"Keimyung University Kidney Institute, Daegu, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pcd.2018.02.001","article-title":"SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis","volume":"12","author":"Seidu","year":"2018","journal-title":"Prim Care Diabetes"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3810\/pgm.2013.05.2667","article-title":"Effects of dapagliflozin on cardiovascular risk factors","volume":"125","author":"Ptaszynska","year":"2013","journal-title":"Postgrad Med"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"R5-20230914","first-page":"17","article-title":"The cardiovascular benefits associated with the use of sodium-glucose cotransporter 2 inhibitors\u2014real-world data","volume":"14","author":"Baptist","year":"2018","journal-title":"Eur Endocrinol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11892-018-1038-9","article-title":"SGLT2 inhibitors and cardiovascular outcomes: current perspectives and future potentials","volume":"18","author":"Jia","year":"2018","journal-title":"Curr Diab Rep"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mehy.2018.02.025","article-title":"SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant","volume":"114","author":"Finucane","year":"2018","journal-title":"Med Hypotheses"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.diabres.2014.02.014","article-title":"SGLT2 inhibitors in the treatment of type 2 diabetes","volume":"104","author":"Hasan","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J Diabetes Investig"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bcpt.12457","article-title":"Diabetic ketoacidosis in a patient with type 2 diabetes after initiation of sodium-glucose cotransporter 2 inhibitor treatment","volume":"118","author":"Storgaard","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.2337\/dc16-2793","article-title":"Incidence of ketoacidosis in the Danish type 2 diabetes population before and after introduction of sodium-glucose cotransporter 2 inhibitors-a nationwide, retrospective cohort study, 1995\u20132014","volume":"40","author":"Jensen","year":"2017","journal-title":"Diabetes Care"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40262-015-0264-4","article-title":"Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"54","author":"Scheen","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.2337\/dc17-1583","article-title":"Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998-2013: a retrospective cohort study","volume":"41","author":"Zhong","year":"2018","journal-title":"Diabetes Care"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.metabol.2006.09.010","article-title":"Admissions for diabetic ketoacidosis in ethnic minority groups in a city hospital","volume":"56","author":"Nyenwe","year":"2007","journal-title":"Metabolism"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4158\/EP.13.3.283","article-title":"Ketosis-prone type 2 diabetes: effect of hyperglycemia on beta-cell function and skeletal muscle insulin signaling","volume":"13","author":"Umpierrez","year":"2007","journal-title":"Endocr Pract"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jemermed.2016.07.082","article-title":"Euglycemic diabetic ketoacidosis with elevated acetone in a patient taking a sodium-glucose cotransporter-2 (SGLT2) inhibitor","volume":"52","author":"Andrews","year":"2017","journal-title":"J Emerg Med"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/phar.1881","article-title":"SGLT2 inhibitors: a systematic review of diabetic ketoacidosis and related risk factors in the primary literature","volume":"37","author":"Burke","year":"2017","journal-title":"Pharmacotherapy"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201901180-00067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:32:59Z","timestamp":1694719979000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201901180-00067"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014150","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}